MXCT

MaxCyte Inc

Add to Watchlist

Advanced Chart

1.340

+0.02(1.515%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.340

Open

1.340

VWAP

1.34

Vol

100.00

Mkt Cap

140.47M

Low

1.340

Amount

134.00

EV/EBITDA(TTM)

Total Shares

104.54M

13.91M

EV/OCF(TTM)

P/S(TTM)

3.90

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

8.75M

+7.17%

-0.110

-0%

9.39M

+7.97%

-0.095

-5%

9.48M

-8.73%

-0.120

+20%

Estimates Revision

The market is revising Downward the revenue expectations for MaxCyte, Inc. (MXCT) for FY2025, with the revenue forecasts being adjusted by -0.38% over the past three months. During the same period, the stock price has changed by -40.97%.

Revenue Estimates for FY2025

Revise Downward

-0.38%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.73%

In Past 3 Month

Stock Price

Go Down

-40.97%

In Past 3 Month

5 Analyst Rating

405.97% Upside

Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is 6.78 USD with a low forecast of 4.84 USD and a high forecast of 8.72 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

405.97% Upside

Current: 1.340

Low

4.84

Averages

6.78

High

8.72

405.97% Upside

Current: 1.340

Low

4.84

Averages

6.78

High

8.72

BTIG

Buy

Neutral

downgrade

2025-08-11

New

Reason

BTIG

Price Target

2025-08-11

New

downgrade

Buy

Neutral

Reason

BTIG downgraded MaxCyte to Neutral from Buy without a price target after \"a tough Q2 business update\" and lowering of the bar for 2025. MaxCyte lowered its 2025 revenue guide by $5M, or 14% of its business, citing ongoing challenges for many of its cell and gene therapy customers to obtain capital to fund programs, purchase capital, or lease its systems, the analyst noted. The firm thinks the company still has a best-in-class electroporation platform, arguing that the \"number one driver to turn the business around is simply its customers becoming more readily able to raise money and invest in more programs.\"

William Blair

Matt Larew

Outperform -> Market Perform

downgrade

2025-08-07

New

Reason

William Blair

Matt Larew

Price Target

2025-08-07

New

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Matt Larew downgraded MaxCyte to Market Perform from Outperform following the earnings report. The company reported a miss and guidance reduction in a strong bioprocessing tools tape, the analyst tells investors in a research note. The firm attributes the miss to MaxCyte's customer exposure and less visible revenue profile. William Blair believes the company's visibility seems lower than peers.

Stephens

Overweight

initiated

2025-07-21

Reason

Stephens

Price Target

2025-07-21

initiated

Overweight

Reason

Stephens initiated coverage of MaxCyte with an Overweight rating and $6 price target. The company is in the early stages of making prudent investments in offerings that expand its reach of the market, the analyst tells investors in a research note. The firm added that while this strategy is still in the early innings, it believe the strategy has the potential to drive long-term revenue growth.

Stifel

Daniel Arias

Strong Buy

Maintains

$11 → $9

2025-03-12

Reason

Stifel

Daniel Arias

Price Target

$11 → $9

2025-03-12

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on MaxCyte to $9 from $11 and keeps a Buy rating on the shares. Management's guidance for 2025 positions core revenues as up 8%-15%, notes the analyst, who adds that there "does appear to be upside potential to the guide," most notably from an embedded assumption that end markets do not improve. The firm continues to like MaxCyte as a play on what should be a rebound year for cell therapy, but "the pace at which the thesis plays out could be on the slower side," the analyst added.

See All Ratings

Valuation Metrics

The current forward P/E ratio for MaxCyte Inc (MXCT.O) is -3.15, compared to its 5-year average forward P/E of -17.61. For a more detailed relative valuation and DCF analysis to assess MaxCyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.61

Current PE

-3.15

Overvalued PE

-1.66

Undervalued PE

-33.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-18.17

Current EV/EBITDA

-0.93

Overvalued EV/EBITDA

7.21

Undervalued EV/EBITDA

-43.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

13.11

Current PS

4.02

Overvalued PS

20.94

Undervalued PS

5.27